Volume 12, Issue 46 (7-2003)                   JGUMS 2003, 12(46): 49-55 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Yousefi Mashhour M, Foroutan H, Mansour Ghanaei F, Ghofrani H. Effects of Lamivudine on Function of Liver and Clinical Condition in Patients with Decompensated Cirrhosis. JGUMS 2003; 12 (46) :49-55
URL: http://journal.gums.ac.ir/article-1-740-en.html
Abstract:   (7828 Views)
Introduction: Decompensated cirrhosis resulting from chronic hepatitis B causes a significant decrease in survival of these patients. Prescription of Alpha interfrone for these patients is forbidden. Several studies have shown the effectiveness of Lamivudine in decreasing the Symptoms arising from this decompensation. Objective: The aim of this study is to determine the effect of Lamivudine on liver function and clinical status of the patients with decompensated cirrhosis arising from HBV presenting to the Supporting Center of patients with liver diseases or those being hospitalized at Gastrology Department of Imam Khomeini Hospital. Materials and methods: In a clinical trial on the basis of liver consideration in 55 patients with cirrhosis that had positive HbsAg, positive HBV DNA, child-pugh score more than 8, but not with positive HCV Ab or positive HIV Ab and creatinin of serum, more than 2 mg/dl, they were treated with 100 mg of Lamivudine tablets daily.In these patients, serum level of bilirubin, albumin, ALT, AST and also the PT coagulation time (on the basis of INR) were controlled at the beginning of study and then at intervals of 2 to 6 months and finally 12 months after the start of treatment and in terms of presence and intensity of ascites and encephalopathy, the patients were examined by a physician. Also at the beginning of the study and 6 and 12 months later, HBs, Ag, HBV DNA, Hbe Ag and Hbe Ab were checked. On the basis of the table related to child-pugh, its amount was calculated at the beginning of the study and at intervals of 2 to 6 months and then 12 months. Results: 5 patients died in the first 6 months of treatments. The following results are related to 50 patients being under treatment with Lamivudine at least for a period of 6 months. In these patients mean child-pugh score was decreased from 11±2 (mean ± criterion deviation) to 7±1 (p<.0001), mean level of bilirubin from 4.5±2 to 1.3±1.6 mg/dl (p<.0001) and mean level of albumin from 2.6±2 to 3.8±1.3 g/dl (p<.0001) and mean PT (INR) from 1.7±2 to 1.2±2 (p<.0001) and mean ALT from 98±10 to 32±10 units per liter (p<.0001). Out of 19 patients not being precormutant, 4 patients (22%) had Hbe Ag seroconversion after 6 months of treatments and 5 (26%) after a 12-month treatment with Lamivudine. All of the patients tolerated this drug very well. Conclusion: Lamivudine can be effective in improvement of liver function in patients with decompensated liver cirrhosis resulting from HBV, but for determination of proper period of treatment, further studies are necessary.
Full-Text [PDF 144 kb]   (2515 Downloads)    
Review Paper: Research | Subject: Special
Received: 2014/09/20 | Accepted: 2014/09/20 | Published: 2014/09/20

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb